Study Stopped
Coral underwent an APA and is no longer in operation
Predicting Medication Response for Autoimmune Disease
REEF
2 other identifiers
observational
200
1 country
1
Brief Summary
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients. Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate. Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled. A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2020
CompletedFirst Submitted
Initial submission to the registry
July 30, 2021
CompletedFirst Posted
Study publicly available on registry
August 9, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2022
CompletedMay 19, 2023
May 1, 2023
1.9 years
July 30, 2021
May 18, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Prediction of medication response
AUC measure
retrospective and 6 months prospectively
Secondary Outcomes (2)
Prediction of disease severity
at enrollment
Classification of disease
at enrollment
Study Arms (5)
Ulcerative Colitis
Crohn's Disease
Rheumatoid Arthritis
Psoriasis
Control
Interventions
A novel clinical test to predict autoimmune medication response
Eligibility Criteria
Study population will include adults 18 years and older who have been diagnosed with one of the four autoimmune conditions.
You may qualify if:
- Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis
- On or about to begin a treatment for condition above
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Coral Genomics, Inc.
San Francisco, California, 94107, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 30, 2021
First Posted
August 9, 2021
Study Start
September 1, 2020
Primary Completion
August 1, 2022
Study Completion
August 1, 2022
Last Updated
May 19, 2023
Record last verified: 2023-05
Data Sharing
- IPD Sharing
- Will share
Data will be shared in the NIH dbGAP repository